Drug Profile
Research programme: human blood coagulation factors - Glycotope/ Octapharma
Alternative Names: FVII-GEXLatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Glycotope
- Developer Glycotope; Octapharma
- Class Coagulants; Recombinant proteins
- Mechanism of Action Factor VIII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Haemophilia in Germany
- 28 Nov 2019 No recent reports of development identified for preclinical development in Haemophilia in Switzerland
- 30 Nov 2015 Glycotope and Octapharma agree to co-develop human blood coagulation factors in Germany and Switzerland for Coagulation disorders